Sparfloxacin
Alternative Names: AT 4140; CI 978; PD 131501; RP 64206; Spara; ZagamLatest Information Update: 05 Apr 2022
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer AbbVie; Sam-A Corporation; Sumitomo Pharma; Sun Pharmaceutical Industries; Teva Pharmaceutical Industries
- Class Antibacterials; Fluoroquinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bacterial infections; Pneumonia; Respiratory tract infections
- Market Withdrawal Acute exacerbations of chronic bronchitis; Community-acquired pneumonia